Retinitis Pigmentosa (Retinitis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update

Pages: 318 Published: December 30, 2021 Report Code: GMDGDHC13215IDB

  • Overview
  • Key Players
  • Contents
  • Tables
  • Figures
  • FAQ
  • Listen
    TTS

Retinitis Pigmentosa (RP) refers to a group of diseases that cause slow but progressive vision loss. Retinitis pigmentosa is caused by a genetic defect. Symptoms include night blindness and loss of peripheral vision. The predisposing factors include autosomal dominant inheritance, autosomal recessive inheritance, and x-linked inheritance.

The Retinitis Pigmentosa drugs in development market research report provide comprehensive information on the therapeutics under development for Retinitis Pigmentosa, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Retinitis Pigmentosa and features dormant and discontinued projects.

What are the key targets in the Retinitis Pigmentosa pipeline products market?

The key targets in the Retinitis Pigmentosa pipeline products market are Rhodopsin, Usherin, X Linked Retinitis Pigmentosa GTPase Regulator, Aryl Hydrocarbon Interacting Protein Like 1, Cyclic Nucleotide Gated Channel, Nucleoredoxin Like Protein 1, Pigment Epithelium Derived Factor, Rod cGMP Specific 3′,5′-Cyclic Phosphodiesterase Subunit Alpha, Transitional Endoplasmic Reticulum ATPase (Valosin Containing Protein or 15S Mg, U4/U6 Small Nuclear Ribonucleoprotein Prp31, and others.

Retinitis Pigmentosa Pipeline Products Analysis Market by Targets

Retinitis Pigmentosa Pipeline Products Analysis Market by Targets

For more target insights, download a free report sample

What are the key mechanisms of action in the Retinitis Pigmentosa pipeline products market?

The key mechanisms of action in the Retinitis Pigmentosa pipeline products market are Usherin Activator, X Linked Retinitis Pigmentosa GTPase Regulator Activator, Rhodopsin Inhibitor, Rhodopsin Activator, Aryl Hydrocarbon Interacting Protein Like 1 Activator, Cyclic Nucleotide Gated Channel Blocker, Nucleoredoxin Like Protein 1 Activator, Pigment Epithelium Derived Factor Activator, Rod cGMP Specific 3′,5′-Cyclic Phosphodiesterase Subunit Alpha Activator, Transitional Endoplasmic Reticulum ATPase (Valosin Containing Protein or 15S MgInhibitor, and others.

Retinitis Pigmentosa Pipeline Products Market Analysis by Mechanism of Actions

Retinitis Pigmentosa Pipeline Products Market Analysis by Mechanism of Actions

For more mechanism of actions insights, download a free report sample

What are the key routes of administration in the Retinitis Pigmentosa pipeline products market?

The key routes of administration in the Retinitis Pigmentosa pipeline products market are intravitreal, intraocular, parenteral, ophthalmic, oral, intracerebral, intrathecal, and nasal.

Retinitis Pigmentosa Pipeline Products Market Analysis by Routes of Administration

Retinitis Pigmentosa Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights, download a free report sample

What are the key molecule types in the Retinitis Pigmentosa pipeline products market?

The key molecule types in the Retinitis Pigmentosa pipeline products market are gene therapy, small molecule, antisense oligonucleotide, cell therapy, antisense RNAi oligonucleotide, gene-modified cell therapy, recombinant protein, synthetic peptide, antibody, oligonucleotide, and others.

Retinitis Pigmentosa Pipeline Products Market Analysis by Molecule Type

Retinitis Pigmentosa Pipeline Products Market Analysis by Molecule Type

For more molecule type insights, download a free report sample

Which are the major companies in the Retinitis Pigmentosa pipeline products market?

Some of the major companies in the Retinitis Pigmentosa pipeline products market are ProQR Therapeutics NV, SparingVision SAS, Viridian Therapeutics Inc, 4D Molecular Therapeutics Inc, Applied Genetic Technologies Corp, Astellas Pharma Inc, Beijing Chinagene Tech Co Ltd, Biogen Inc, DTx Pharma Inc, and Eyevensys SAS.

Retinitis Pigmentosa Pipeline Products Market Analysis by Companies

 

Retinitis Pigmentosa Pipeline Products Market Analysis by Companies

To know more about major companies, download a free report sample

Market Report Overview

Key targets Rhodopsin, Usherin, X Linked Retinitis Pigmentosa GTPase Regulator, Aryl Hydrocarbon Interacting Protein Like 1, Cyclic Nucleotide Gated Channel, Nucleoredoxin Like Protein 1, Pigment Epithelium Derived Factor, Rod cGMP Specific 3′,5′-Cyclic Phosphodiesterase Subunit Alpha, Transitional Endoplasmic Reticulum ATPase (Valosin Containing Protein or 15S Mg, U4/U6 Small Nuclear Ribonucleoprotein Prp31, and Others
Key mechanism of action Usherin Activator, X Linked Retinitis Pigmentosa GTPase Regulator Activator, Rhodopsin Inhibitor, Rhodopsin Activator, Aryl Hydrocarbon Interacting Protein Like 1 Activator, Cyclic Nucleotide Gated Channel Blocker, Nucleoredoxin Like Protein 1 Activator, Pigment Epithelium Derived Factor Activator, Rod cGMP Specific 3′,5′-Cyclic Phosphodiesterase Subunit Alpha Activator, Transitional Endoplasmic Reticulum ATPase (Valosin Containing Protein or 15S MgInhibitor, and Others
Key routes of administration Intravitreal, Intraocular, Parenteral, Ophthalmic, Oral, Intracerebral, Intrathecal, and Nasal
Key molecule type Gene Therapy, Small Molecule, Antisense Oligonucleotide, Cell Therapy, Antisense RNAi Oligonucleotide, Gene-Modified Cell Therapy, Recombinant Protein, Synthetic Peptide, Antibody, Oligonucleotide, and Others
Major companies ProQR Therapeutics NV, SparingVision SAS, Viridian Therapeutics Inc, 4D Molecular Therapeutics Inc, Applied Genetic Technologies Corp, Astellas Pharma Inc, Beijing Chinagene Tech Co Ltd, Biogen Inc, DTx Pharma Inc, and Eyevensys SAS

Scope

  • The report provides a snapshot of the global therapeutic landscape of Retinitis Pigmentosa (Retinitis)
  • The report reviews pipeline therapeutics for Retinitis Pigmentosa (Retinitis) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Retinitis Pigmentosa (Retinitis) therapeutics and enlists all their major and minor projects
  • The report assesses Retinitis Pigmentosa (Retinitis) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews the latest news related to pipeline therapeutics for Retinitis Pigmentosa (Retinitis)

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Retinitis Pigmentosa (Retinitis)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Retinitis Pigmentosa (Retinitis) pipeline depth and focus on Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from the pipeline

Key Players

4D Molecular Therapeutics Inc

AbbVie Inc

Aldeyra Therapeutics Inc

Allegro Ophthalmics LLC

Alpine Biotherapeutics Corp

Anida Pharma Inc

Ankar Pharma SL

Applied Genetic Technologies Corp

Astellas Pharma Inc

Bayon Therapeutics Inc

Beijing Chinagene Tech Co Ltd

Biogen Inc

Brighton Biotech Inc

Casebia Therapeutics LLP

CIRC Biosciences Inc

Coave Therapeutics

Copernicus Therapeutics Inc

Curative Biotechnology Inc

Dompe Farmaceutici SpA

DTx Pharma Inc

Editas Medicine Inc

EmendoBio Inc

Emerald Organic Products Inc

Endogena Therapeutics Inc

EyePoint Pharmaceuticals Inc

Eyestem Research Pvt Ltd

Eyevensys SAS

GenSight Biologics SA

Grupo Ferrer Internacional S.A.

ID Pharma Co Ltd

InFlectis BioScience SAS

IVERIC bio Inc

jCyte Inc

Kubota Vision Inc

Kyoto Drug Discovery & Development Co Ltd

Limnopharma SL

Lineage Cell Therapeutics Inc

Locanabio Inc

MeiraGTx Holdings Plc

MimeTech Srl

Mireca Medicines GmbH

Mitochem Therapeutics, LLC

Nanoscope Therapeutics Inc

Nanovector srl

Navega Therapeutics Inc

Novartis AG

Ocugen Inc

OiDE OptoEye Inc

OliX Pharmaceuticals Inc

ONL Therapeutics Inc

Opsis Therapeutics LLC

OptiKira LLC

Precision Biosciences Inc

Profarma

Prolindox Inc

ProQR Therapeutics NV

PYC Therapeutics Ltd

ReNeuron Group Plc

ResQ Biotech

Rznomics Inc

SanBio Co Ltd

SparingVision SAS

Staidson BioPharma Inc

Sumitomo Dainippon Pharma Co Ltd

SunRegen Healthcare AG

Sylentis SAU

Variant

ViGeneron GmbH

Viridian Therapeutics Inc

Wave Life Sciences Ltd

Worphmed Srl

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Retinitis Pigmentosa (Retinitis) – Overview

Retinitis Pigmentosa (Retinitis) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Retinitis Pigmentosa (Retinitis) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Retinitis Pigmentosa (Retinitis) – Companies Involved in Therapeutics Development

Retinitis Pigmentosa (Retinitis) – Drug Profiles

Retinitis Pigmentosa (Retinitis) – Dormant Projects

Retinitis Pigmentosa (Retinitis) – Discontinued Products

Retinitis Pigmentosa (Retinitis) – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Retinitis Pigmentosa (Retinitis), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Target, 2021 (Contd..1)

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Mechanism of Action, 2021 (Contd..1)

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Retinitis Pigmentosa (Retinitis) – Dormant Projects, 2021

Retinitis Pigmentosa (Retinitis) – Dormant Projects, 2021 (Contd..1)

Retinitis Pigmentosa (Retinitis) – Dormant Projects, 2021 (Contd..2)

Retinitis Pigmentosa (Retinitis) – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Retinitis Pigmentosa (Retinitis), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

Frequently Asked Questions

The key targets in the Retinitis Pigmentosa pipeline products market are Rhodopsin, Usherin, X Linked Retinitis Pigmentosa GTPase Regulator, Aryl Hydrocarbon Interacting Protein Like 1, Cyclic Nucleotide Gated Channel, Nucleoredoxin Like Protein 1, Pigment Epithelium Derived Factor, Rod cGMP Specific 3′,5′-Cyclic Phosphodiesterase Subunit Alpha, Transitional Endoplasmic Reticulum ATPase (Valosin Containing Protein or 15S Mg, U4/U6 Small Nuclear Ribonucleoprotein Prp31, and others.

The key mechanisms of action in the Retinitis Pigmentosa pipeline products market are Usherin Activator, X Linked Retinitis Pigmentosa GTPase Regulator Activator, Rhodopsin Inhibitor, Rhodopsin Activator, Aryl Hydrocarbon Interacting Protein Like 1 Activator, Cyclic Nucleotide Gated Channel Blocker, Nucleoredoxin Like Protein 1 Activator, Pigment Epithelium Derived Factor Activator, Rod cGMP Specific 3′,5′-Cyclic Phosphodiesterase Subunit Alpha Activator, Transitional Endoplasmic Reticulum ATPase (Valosin Containing Protein or 15S MgInhibitor, and others.

The key routes of administration in the Retinitis Pigmentosa pipeline products market are intravitreal, intraocular, parenteral, ophthalmic, oral, intracerebral, intrathecal, and nasal.

The key molecule types in the Retinitis Pigmentosa pipeline products market are gene therapy, small molecule, antisense oligonucleotide, cell therapy, antisense RNAi oligonucleotide, gene-modified cell therapy, recombinant protein, synthetic peptide, antibody, oligonucleotide, and others.

Some of the major companies in the Retinitis Pigmentosa pipeline products market are ProQR Therapeutics NV, SparingVision SAS, Viridian Therapeutics Inc, 4D Molecular Therapeutics Inc, Applied Genetic Technologies Corp, Astellas Pharma Inc, Beijing Chinagene Tech Co Ltd, Biogen Inc, DTx Pharma Inc, and Eyevensys SAS.

$2500

Can be used by individual purchaser only

$7500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.